// App-Quantinova.ai

PB2099 : A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-1607, A FIRST-IN-CLASS ORAL CBL-B INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING RICHTER TRANSFORMATION DLBCL

Researchers

Presenter

  • Adam Sharp

Principal Investigators

  • Anja Williams

  • Sarah Blagden

  • Ruth Plummer

  • Daniel Hochhauser

  • Simon Pacey

  • Jeff Evans

  • Srinand Nandakumar

  • Seema Rogers

  • Katherine L. Jameson

  • Johann de Bono

  • Hendrik-Tobias Arkenau

Medical Centers

  • University of Manchester,Manchester,Regno Unito

  • Cambridge Cancer Centre (CCC),Cambridge,Verenigd Koninkrijk

  • Northern Centre for Care,Newcastle upon Tyne,Royaume-uni

  • The Institute of Cancer Research, London,London,Vereinigtes Königreich

  • The Institute of Cancer Research, London,London,Соединённое Королевство

  • Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom

  • University of Glasgow,Glasgow,Royaume-uni

  • Sarah Cannon Research Institute (SCRI),London,Storbritannien

  • The Institute of Cancer Research, London, UK

  • The Institute of Cancer Research, London,London,Vereinigtes Königreich

  • University of Oxford, Oxford, United Kingdom

  • Sarah Cannon Research Institute (SCRI),London,Verenigd Koninkrijk

  • University College London Hospitals,London,Vereinigtes Königreich

  • Sarah Cannon Research Institute, London, United Kingdom

  • University of Glasgow, Glasgow, United Kingdom

  • University of Manchester,Manchester,Royaume-uni

  • Cambridge Cancer Centre (CCC),Cambridge,Соединённое Королевство

  • Nurix Therapeutics, Inc.,San Francisco,Estados Unidos

  • University College London,London,Reino Unido

  • QED Therapeutics Inc., San Francisco, United States

  • University of Oxford,Oxford,Reino Unido

  • University of Manchester,Manchester,Vereinigtes Königreich

  • Northern Centre for Care,Newcastle upon Tyne,Verenigd Koninkrijk

  • Nurix Therapeutics, Inc.,San Francisco,Verenigde Staten

  • Cambridge Cancer Centre (CCC),Cambridge,Verenigd Koninkrijk

  • The Institute of Cancer Research, London,London,Storbritannien

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • University of Glasgow,Glasgow,Vereinigtes Königreich

  • Nurix Therapeutics, Inc.,San Francisco,Estados Unidos

  • Royal Marsden Hospital,Wallington,USA

  • The Christie NHS Foundation Trust,Manchester,Storbritannien

  • Cambridge Cancer Centre (CCC),Cambridge,Regno Unito

  • Royal Marsden Hospital,Wallington,Vereinigte Staaten

  • Royal Marsden Hospital,Wallington,Vereinigte Staaten

  • The Christie NHS Foundation Trust, Manchester,

  • Nurix Therapeutics, Inc.,San Francisco,Estados Unidos

  • Sarah Cannon Research Institute (SCRI),London,Соединённое Королевство

  • University of Manchester,Manchester,Соединённое Королевство

  • The Christie NHS Foundation Trust, Manchester,

  • University of Glasgow,Glasgow,Regno Unito

  • University of Oxford,Oxford,Соединённое Королевство

  • Institute for Cancer Research, London, United Kingdom

  • Haematology,University College London,London,Royaume-uni

  • The Institute of Cancer Research, London, UK

  • University of Oxford,Oxford,Royaume-uni

  • University of Oxford,Oxford,Vereinigtes Königreich

  • Haematology,The Christie NHS Foundation Trust,Manchester,Vereinigtes Königreich

  • The Christie NHS Foundation Trust, Manchester,

  • Sarah Cannon Research Institute (SCRI),London,Reino Unido

  • Northern Centre for Care,Newcastle upon Tyne,Соединённое Королевство

  • University College London (UCL),London,Storbritannien

  • The Institute of Cancer Research, London,London,Vereinigtes Königreich

  • Sarah Cannon Research Institute (SCRI),London,Reino Unido

  • Cambridge Cancer Centre (CCC),Cambridge,Storbritannien

  • University of Glasgow,Glasgow,Storbritannien

  • University of Glasgow,Glasgow,Соединённое Королевство

  • The Institute of Cancer Research, London,London,Storbritannien

  • Cambridge Cancer Centre, Cambridge, United Kingdom

  • University of Manchester,Manchester,Storbritannien

  • University of Oxford,Oxford,Verenigd Koninkrijk

  • Cambridge Cancer Centre (CCC),Cambridge,Regno Unito

  • Nurix Therapeutics, Inc.,San Francisco,Verenigde Staten

  • Institute for Cancer Research, London, United Kingdom

  • Haematology,The Christie NHS Foundation Trust,Manchester,Vereinigtes Königreich

  • Royal Marsden Hospital,Wallington,Vereinigte Staaten

  • Sarah Cannon Research Institute (SCRI),London,Reino Unido

  • Sarah Cannon Research Institute (SCRI),London,Verenigd Koninkrijk

  • University of Manchester, Manchester, United Kingdom

  • University of Manchester,Manchester,Regno Unito

  • Northern Centre for Care,Newcastle upon Tyne,Royaume-uni

  • University of Oxford,Oxford,Reino Unido

  • University of Glasgow,Glasgow,Regno Unito

  • The Institute of Cancer Research, London,London,Vereinigtes Königreich

  • Northern Centre for Care,Newcastle upon Tyne,Verenigd Koninkrijk

  • Northern Centre for Care,Newcastle upon Tyne,Royaume-uni

  • University College London,London,Reino Unido

  • Kings College London, London, United Kingdom

  • University College London Hospitals,London,Vereinigtes Königreich

  • Northern Centre for Care,Newcastle upon Tyne,Storbritannien

  • University College London,London,Соединённое Королевство

  • Cambridge Cancer Centre (CCC),Cambridge,Royaume-uni

  • The Christie NHS Foundation Trust,Manchester,Соединённое Королевство

  • University of Glasgow,Glasgow,Verenigd Koninkrijk

  • University of Manchester,Manchester,Verenigd Koninkrijk

  • The Institute of Cancer Research, London,London,Соединённое Королевство

  • University of Oxford,Oxford,Storbritannien

  • Nurix Therapeutics, Inc.,San Francisco,Estados Unidos

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Unspecified Cancer

  • Diffuse large B-cell lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

  • Open Label

  • Multicenteric

  • Dose Escalation

  • First-In-Human

Phase

  • I

Study Id's

  • NCT05107674

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved